Correction to: Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study

Srishti Joshi¹ · Anurag S. Rathore¹

Published online: 4 September 2020
© Springer Nature Switzerland AG 2020

Correction to: BioDrugs (2020) 34:209–223
<https://doi.org/10.1007/s40259-020-00404-3>

Page 215, Section “3.1.2 Primary Structure: Peptide Mapping, Posttranslational Modification, and Degradation Product Identification”, left column, second paragraph:

The sentence, which previously read:

“No significant difference (Student’s t test) was observed in any of the biosimilars relative to the originator for oxidation at M255 and M431 (Fig. 3c; Table 5 in the ESM).”

Should read:

“No significant difference (Student’s t test) was observed in any of the biosimilars relative to the originator for oxidation at M255 and M431 (Fig. 3a; Table 5 in the ESM).”

Page 217, legend to Figure 3 “Glycoform analysis and posttranslational modifications of trastuzumab biosimilars and originator using liquid chromatography mass spectrometry”:

The legend, which previously read:

“Relative quantification of **a** glycoforms for intact trastuzumab samples, **b** glycoforms for reduced trastuzumab samples, and **c** predicted posttranslational modifications for

trastuzumab originator and biosimilars, all normalized to the originator.”

Should read:

“Relative quantification of **a** predicted posttranslational modifications for trastuzumab originator and biosimilars, **b** glycoforms for intact trastuzumab samples, and **c** glycoforms for reduced trastuzumab samples, all normalized to the originator.”

The original article can be found online at <https://doi.org/10.1007/s40259-020-00404-3>.

✉ Anurag S. Rathore
Asrathore@biotechcmz.com

¹ Department of Chemical Engineering, Indian Institute of Technology, Delhi, Hauz Khas, New Delhi 110016, India